Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):e197-e199. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2025.0085

View: 672 Download: 28

Editorial

TM4SF1 - A new immune target for treatment of hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Chen Rui Yuan, Terence Kin Wah Lee

Clin Mol Hepatol. 2025;31(2):646-649. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0102

View: 713 Download: 41

Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma: Editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Valerie Chew

Clin Mol Hepatol. 2025;31(2):642-645. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0031

View: 834 Download: 47 Crossref: 1

Original Article

Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma

Weifeng Zeng, Furong Liu, Yachong Liu, Ze Zhang, Haofan Hu, Shangwu Ning, Hongwei Zhang, Xiaoping Chen, Zhibin Liao, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):489-508. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0934

View: 2378 Download: 304 Crossref: 6

Reply to Correspondence

Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):e121-e122. Published online October 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0886

View: 1018 Download: 37

Correspondence

Correspondence to letter to the editor on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Peng Wei, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e110-e112. Published online October 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0828

View: 1083 Download: 49

Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”

Sun Young Yim, Sung Hwan Lee, Ji Hoon Kim, Sunyoung S Lee, Ahmed O Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e84-e86. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0830

View: 993 Download: 33

Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”

Sung Hwan Lee, Sun Young Yim, Ji Hoon Kim, Sunyoung S. Lee, Ahmed O. Kaseb, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(1):e81-e83. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0829

View: 1072 Download: 35 Crossref: 1

Letter to the Editor

Comprehensive analysis of transcriptomic biomarkers for predicting response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma

Binghua Li, Jingyuan Wen, Zhu Xu, Peng Yan, Bing Han, Decai Yu

Clin Mol Hepatol. 2025;31(1):e31-e34. Published online September 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0628

View: 1285 Download: 109 Crossref: 2

Editorial

Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”

Hiroaki Kanzaki, Yujin Hoshida

Clin Mol Hepatol. 2025;31(1):308-310. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0726

View: 1155 Download: 76 Web of Science: 1 Crossref: 1

Original Article

Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2024;30(4):807-823. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0333 Correction in: Clin Mol Hepatol 2025;31(2):669

View: 3599 Download: 332 Web of Science: 11 Crossref: 6

Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting

Xueshuai Wan, Karin Wisskirchen, Tao Jin, Lu Yang, Xiaorui Wang, Xiang’an Wu, Fang Liu, Yu Wu, Christy Ma, Yong Pang, Qi Li, Ke Zhang, Ulrike Protzer, Shunda Du

Clin Mol Hepatol. 2024;30(4):735-755. Published online May 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0058

View: 3984 Download: 350 Web of Science: 5 Crossref: 8

Letter to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

DOI: https://doi.org/10.3350/cmh.2023.0557

View: 3423 Download: 147 Web of Science: 11 Crossref: 11

Review

Recent advances in the management of hepatocellular carcinoma

Kamya Sankar, Jun Gong, Arsen Osipov, Steven A. Miles, Kambiz Kosari, Nicholas N. Nissen, Andrew E. Hendifar, Ekaterina K. Koltsova, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):1-15. Published online July 21, 2023

DOI: https://doi.org/10.3350/cmh.2023.0125

View: 9872 Download: 453 Web of Science: 48 Crossref: 50

Snapshot

Systemic therapy in advanced hepatocellular carcinoma

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2023;29(2):516-519. Published online February 20, 2023

DOI: https://doi.org/10.3350/cmh.2023.0051

View: 5436 Download: 184 Web of Science: 7 Crossref: 8

Editorial

Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences

Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen

Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023

DOI: https://doi.org/10.3350/cmh.2023.0106

View: 4970 Download: 90 Web of Science: 9 Crossref: 10

Review

Clinical practice guidelines and real-life practice on hepatocellular carcinoma: A the Hong Kong perspective

Rex Wan-Hin Hui, Lung-Yi Mak, Tan-To Cheung, Victor Ho-Fun Lee, Wai-Kay Seto, Man-Fung Yuen

Clin Mol Hepatol. 2023;29(2):217-229. Published online December 28, 2022

DOI: https://doi.org/10.3350/cmh.2022.0399

View: 7642 Download: 263 Web of Science: 15 Crossref: 16

Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma

Pil Soo Sung

Clin Mol Hepatol. 2022;28(3):333-350. Published online October 19, 2021

DOI: https://doi.org/10.3350/cmh.2021.0308

View: 19008 Download: 394 Web of Science: 32 Crossref: 35

Original Article

Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study

Gyu Sang Yoo, Won-Gyun Ahn, Shin-Yeong Kim, Wonseok Kang, Changhoon Choi, Hee Chul Park

Clin Mol Hepatol. 2021;27(1):144-156. Published online December 7, 2020

DOI: https://doi.org/10.3350/cmh.2020.0095

View: 9179 Download: 319 Web of Science: 24 Crossref: 25

Editorial

Long-term prognosis and management of hepatocellular carcinoma after curative treatment

Naoshi Nishida

Clin Mol Hepatol. 2020;26(4):480-483. Published online September 21, 2020

DOI: https://doi.org/10.3350/cmh.2020.0208

View: 6413 Download: 105 Web of Science: 14 Crossref: 13

Review

Treatment options after sorafenib failure in patients with hepatocellular carcinoma

Imane El Dika, Ghassan K. Abou-Alfa

Clin Mol Hepatol. 2017;23(4):273-279. Published online November 20, 2017

DOI: https://doi.org/10.3350/cmh.2017.0108

View: 10362 Download: 241 Web of Science: 31 Crossref: 31

1 |

Viewed By 10962	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7667	MAFLD: How is it different from NAFLD?
Viewed By 5558	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5016	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 4914	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 342	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 316	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search